
Although it only has early phase I data for its vaccine against mosquito-borne equine encephalitis, Bavarian Nordic is excited by the results.
As well as the positive results of the study, the Danish biotech company is also excited about the way the development program is set up. The vaccine is being developed with the US government - a process that Bavarian Nordic has already been through in the development of its smallpox vaccine.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app